Author

Stefan Schreiber

EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA
EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA

Stefan Schreiber  et al.

Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)
Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)

Stefan Schreiber  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)
New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)

Stefan Schreiber  et al.

SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY
SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

Stefan Schreiber  et al.

IBD management: From the present to the future (Fresenius Kabi)
IBD management: From the present to the future (Fresenius Kabi)

Stefan Schreiber  et al.

THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

UEG Research Prize 2020: Therapeutic mechanisms of controlled-ileocolonic-release nicotinamide (CICR-NAM) in IBD
UEG Research Prize 2020: Therapeutic mechanisms of controlled-ileocolonic-release nicotinamide (CICR-NAM) in IBD

Stefan Schreiber

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Stefan Schreiber  et al.

Clinical Advances of Infliximab in IBD treatment: Infliximab SC (Celltrion Healthcare)
Clinical Advances of Infliximab in IBD treatment: Infliximab SC (Celltrion Healthcare)

Stefan Schreiber  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Stefan Schreiber  et al.

TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY

Stefan Schreiber  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Stefan Schreiber  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Stefan Schreiber  et al.

BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY
BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)
Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)

Stefan Schreiber  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Item 1 - 20 / 53
1
2 3